Nick Thatcher
Impact in
- Oncology top 0.5%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 75
- Lung Cancer Research Studies 37
- Colorectal Cancer Treatments and Studies 16
- Cancer Immunotherapy and Biomarkers 11
- Cancer Treatment and Pharmacology 10
-
- Lung Cancer Treatments and Mutations 52
- Lung Cancer Diagnosis and Treatment 15
- Co-authors
- Tudor–Eliade Ciuleanu (10 shared papers)Purvish M. Parikh (4 shared papers)Alex Y. Chang (4 shared papers)Joachim von Pawel (2 shared papers)José Rodrigues Pereira (2 shared papers)Sumitra Thongprasert (3 shared papers)Venice Archer (1 shared paper)E.H. Tan (1 shared paper)
- Journals
- Journal of Thoracic Oncology (19 papers)Journal of Clinical Oncology (14 papers)Cancer (11 papers)Lung Cancer (9 papers)The Lancet Oncology (5 papers)
- Partner nations
- United KingdomUnited StatesGermany
In The Last Decade
Nick Thatcher
120 papers receiving 5.6k citations
Nick Thatcher's Hit Papers
Peers
Comparison fields: 5 of 111
- Oncology 2.9k
- Pulmonary and Respiratory Medicine 3.3k
- Cancer Research 590
- Molecular Biology 1.2k
- Pathology and Forensic Medicine 223
Countries citing papers authored by Nick Thatcher
This map shows the geographic impact of Nick Thatcher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nick Thatcher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nick Thatcher more than expected).
Fields of papers citing papers by Nick Thatcher
This network shows the impact of papers produced by Nick Thatcher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nick Thatcher. The network helps show where Nick Thatcher may publish in the future.
Co-authors
The 25 scholars most cited alongside Nick Thatcher, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 121 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Hit paper breakdown → | 2005 | 1690 |
| 2 | Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2006 | 570 |
| 3 | Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial Hit paper breakdown → | 2015 | 338 |
| 4 | 2010 | 204 | |
| 5 | 2006 | 165 | |
| 6 | 2009 | 159 | |
| 7 | 2017 | 144 | |
| 8 | 2006 | 144 | |
| 9 | 2016 | 118 | |
| 10 | 2006 | 107 | |
| 11 | 2013 | 96 | |
| 12 | A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Working Party. | 1992 | 90 |
| 13 | 2007 | 90 | |
| 14 | 2006 | 90 | |
| 15 | 2012 | 74 | |
| 16 | 2005 | 72 | |
| 17 | 2008 | 61 | |
| 18 | Activity of JM9 in advanced ovarian cancer: a phase I-II trial. | 1985 | 55 |
| 19 | 2005 | 51 | |
| 20 | A method for following human lymphocyte traffic using indium-111 oxine labelling. | 1981 | 51 |
About Nick Thatcher
Nick Thatcher is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Immunology and Epidemiology, having authored 121 papers that have together received 5.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (52 papers), Lung Cancer Research Studies (37 papers), Colorectal Cancer Treatments and Studies (16 papers), Lung Cancer Diagnosis and Treatment (15 papers), Neuroendocrine Tumor Research Advances (13 papers), Cancer Immunotherapy and Biomarkers (11 papers), Cancer therapeutics and mechanisms (11 papers) and Cancer Treatment and Pharmacology (10 papers). The work is most often cited by research in Oncology (2.9k citations), Pulmonary and Respiratory Medicine (3.3k citations), Cancer Research (590 citations), Molecular Biology (1.2k citations) and Pathology and Forensic Medicine (223 citations). Nick Thatcher has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Tudor–Eliade Ciuleanu, Purvish M. Parikh, Alex Y. Chang, Joachim von Pawel, José Rodrigues Pereira, Sumitra Thongprasert, Venice Archer, E.H. Tan, Kevin Carroll and Kristine Pemberton. Their work appears in journals such as Journal of Thoracic Oncology, Journal of Clinical Oncology, Cancer, Lung Cancer and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.